A study testing whether a study medicine from Amgen, Maridebart Cafraglutide, can help people lose weight.

Recruiting now. Registry record last updated July 23, 2026.

Who can join: Adults 18 to 99, have obesity or are overweight, BMI 25+.
What you take: Maridebart Cafraglutide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The full study runs about 1.8 years; your own time in it is usually shorter.
What you get: Many clinical trials pay for the study medication and the study visits. Some also pay for travel. Ask the study team what this one covers before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 3Sponsor AmgenDrug Maridebart CafraglutideClass OtherSites 43 USEnrollment target 300

What this study is for

Primary condition: Obesity or Overweight.

Full scientific study title: Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults.

Who can join

Age18 to 99SexAnyBMI25 or higher

Adults 18 to 99, have obesity or are overweight, BMI 25+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Body Mass Index (BMI) ≥ 25 at screening.
Weight loss of ≥ 10% on weekly GLP-1 RA.
Stable body weight.
Stable dose of GLP-1RA.
Stable gastrointestinal (GI) tolerability.

Key exclusion criteria

Obesity induced by other endocrine disorders (ex: Cushing's syndrome).
Previous or planned surgical, endoscopic or device-based treatment for obesity.
History of malignancy.
Type 1/Type 2 diabetes mellitus (DM).
Family or personal history of medullary thyroid cancer.

Where this trial is enrolling

This trial has 43 sites across 17 states. Contact a site coordinator directly to start screening.

Find a site near you

Alabama1 site

Cahaba Research, Inc.
Pelham, Alabama

Arizona2 sites

Arizona Clinical Trials
Chandler, Arizona
Epic Medical Research - Sun City
Sun City, Arizona

California5 sites

Desert Oasis Healthcare Medical Group
Palm Springs, California
Inland Empire Liver Foundation
Rialto, California
Peninsula Research Associates
Rolling Hills Estates, California
Apex Clinical Research
San Diego, California
Southern California Clinical Research
Santa Ana, California

Florida9 sites

University of Florida Department of Medicine
Gainesville, Florida
Aga Clinical Trials
Hialeah, Florida
South Florida Clinical Research
Margate, Florida
New Horizon Research Center
Miami, Florida
Research Institute of South Florida
Miami, Florida
Clinical Neuroscience Solutions
Orlando, Florida
Florida Institute for Clinical Research
Orlando, Florida
Progressive Medical Research
Port Orange, Florida
Charter Research - The Villages
The Villages, Florida

Georgia3 sites

Nsc Research
Johns Creek, Georgia
Rophe Adult and Pediatric Medicine/Sky Clinical Research Network Group
Union City, Georgia
North Georgia Clinical Research
Woodstock, Georgia

Idaho1 site

Solaris Clinical Research
Meridian, Idaho

Illinois1 site

Endeavor Health
Skokie, Illinois

Louisiana1 site

Pennington Biomedical Research Center
Baton Rouge, Louisiana

Michigan1 site

Arcturus Healthcare, Public Limited Company, Troy Internal Medicine Research Division
Troy, Michigan

Mississippi1 site

Sky Integrative Medical Center
Ridgeland, Mississippi

Nevada1 site

Excel Clinical Research
Las Vegas, Nevada

New York2 sites

Icahn School of Medicine at Mount Sinai
New York, New York
Rochester Clinical Research
Rochester, New York

North Carolina3 sites

Centricity Research Morehead City Specialty
Morehead City, North Carolina
Accellacare of Raleigh
Raleigh, North Carolina
Accellacare Research of Wilmington
Wilmington, North Carolina

Oklahoma2 sites

Epic Medical Research - Oklahoma
Chickasha, Oklahoma
Lynn Health Science Institute
Oklahoma City, Oklahoma

Pennsylvania1 site

Altoona Center for Clinical Research
Duncansville, Pennsylvania

Texas8 sites

Epic Medical Research - DeSoto
DeSoto, Texas
South Texas Research Institute
Edinburg, Texas
Biopharma Informatic, LLC
Houston, Texas
Research Physicians Network, LLC
Houston, Texas
Texas Institute of Cardiology
McKinney, Texas
North Hills Medical Research
North Richland Hills, Texas
VIP Trials
San Antonio, Texas
Northwest Houston Heart Center
Tomball, Texas

Washington1 site

Eastside Research Associates Health Research
Redmond, Washington

Follow this trial

We email you if NCT07575399 changes status, adds new sites in your state, or if a similar trial opens for the same condition. No spam, opt out any time.

Timeline

Started enrolling: May 11, 2026. Expected completion: February 28, 2028. Last updated on ClinicalTrials.gov: July 23, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked August 21, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site · LinkedIn · Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.